



The Nifty ended 0.86% up at 17233.25. It opened on a positive note and remained buoyant till the end towards ending in green. However, critical resistance placed around 17300 is still intact. Hence, staying cautious on rise is advised. Trading range is likely to be 17000-17300. However, on the flip side, successful closing above 17300 may push the Benchmark Index further higher towards 17500.

On the Nifty hourly chart, direction of the leading indicators suggesting upside is limited till 17300 as of now. Short-term trading range is likely to be 17000-17300.

Nifty patterns on multiple periods suggest; the benchmark index ended in green. However, critical resistance placed around 17300 yet to be taken out. Chart pattern suggesting range-bound oscillation to continue.

Nifty Crucial Supports & Resistances-

Supports- 17100, 17000 Resistances- 17300, 17500

Open Positional Calls-

T+10 POSITIONAL SELL
|Futures Segment| GRASIM Fut @ 1610-1620, TGT- 1520, Closing SL- closing above 1670

T+5 Positional Sell-
|Futures Segment| SAIL Fut @ 111-112, TGT- 102, Closing SL- closing above 117

T+10 POSITIONAL SELL
|Futures Segment| SBIN Fut @ 460-465, TGT- 435, SL- closing above 480

T+2 BUY
|Cash Segment| TCS @ 3690-3680, TGT- 3760, SL- closing below 3640

T+10 INST POSITIONAL SELL
|Futures Segment| ICICI BANK Jan Fut @ 740-745, TGT - 705, SL- closing above 765

T+14 INST POSITIONAL SELL
|Futures Segment| UPL Jan Fut @ 770-775, TGT- 705, SL- closing above 810

BTST
|Cash Segment| IPCA LAB @ 2080-2070, TGT- 2110, SL - closing below 2050

Key Contents

Domestic News

Page No.

4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks advanced for the second consecutive session, aided by gains in auto, information technology, healthcare, metal and consumer durables stocks. Concerns over the economic impact due to omicron strain of covid-19 intensified after Delhi government introduced yellow alert restrictions to prevent the spread of the omicron variant.

Nifty index ended 0.86% higher at 17,233. The broader markets represented by the NIFTY 500 Index ended 0.95% higher, ending at 14,868. Among the sectorial indices all indices ended positive, among them NIFTY Auto was the top gainer, gaining by 1.34%, followed by NIFTY PSE was gaining by 1.20%.

Asian Paints was the top gainer, gaining by 2.93%, followed by Sun Pharma and M&M gained by 2.64% & 2.46% respectively. Indusind Bank was the top loser, losing by 0.30%, followed by Power Grid and ICICI Bank which fell by 0.24% & 0.03% respectively.

The Advance : Decline ratio stood at 1612:476

Market Turnover (In Crore) 28-12-2021

Name	Last	Previous
NSE Cash	*NA	40153.50
NSE F&O	*NA	5400111.97
BSE Cash	3,507.44	3,459.10
BSE F&O	*NA	109.29

FII Derivatives Flow (In Crore) 27-12-2021*

Instrument	Purchase	Sale	Net
Index Future	5655.80	5600.53	55.27
Index Option	400519.08	392575.74	7943.34
Stock Future	37543.19	37005.86	537.33
Stock Option	16166.19	15850.43	315.76

Institutional Flow (In Crore) 27-12-2021*

Institution	Purchase	Sale	Net
FII	1996.94	3035.19	1038.25
DII	4016.54	3060.75	955.79

*Data not updated till 5:45PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Asian Paints	2.93	2.96	1211648	735118
Sun Pharma	2.64	4.69	5477769	4484545
M&M	2.46	3.26	1677680	1602433
Ultratech Cement	2.22	1.07	185895	204697
Titan	2.08	4.03	871453	642438

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
ICICI Bank	0.03	2.14	17833655	10231320
Power Grid	0.24	0.48	11802155	9881009
Indusind Bank	0.30	0.53	4660498	5123715

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	57897.48	477.24	0.83	2.80	1.38	2.97	22.27
Nifty	17233.25	147.00	0.86	2.76	1.21	2.90	24.22
BSE M Cap	24653.89	231.90	0.95	2.55	0.78	1.45	38.32
BSE S Cap	28922.89	407.97	1.43	3.78	3.03	3.98	61.23
Nifty MC 100	30094.85	351.70	1.18	3.04	0.58	0.48	45.26
BSE Auto	24433.24	303.53	1.26	2.99	0.42	1.42	19.12
BSE Capgoods	28584.49	438.78	1.56	3.73	5.64	9.38	53.14
BSE FMCG	13635.24	106.00	0.78	2.34	0.82	8.91	8.08
BSE Metal	19263.67	168.75	0.88	1.29	2.99	3.06	66.80
BSE Oil&Gas	17593.36	154.75	0.89	2.85	1.07	3.06	24.62
BSE Healthcare	25424.24	199.71	0.79	3.63	0.79	1.40	17.44
BSE Power	3518.26	30.06	0.86	1.40	0.55	14.44	69.97
BSE Realty	3833.83	29.25	0.77	5.00	0.43	3.99	58.20
BSE ConsDur	43731.44	536.91	1.24	3.30	4.32	7.09	46.52
BSE Bank	40026.93	135.42	0.34	1.82	2.65	7.75	12.91
BSE IT	37506.40	369.91	1.00	4.48	10.84	8.57	55.33

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.47	0.01	0.35	0.60	0.18	4.36	59.29
UK	0.93	0.00	0.00	19.82	12.12	2.84	259.92
Brazil	4.58	0.01	0.13	1.84	8.14	8.74	40.29
Japan	0.06	0.00	3.28	18.87	14.87	25.88	152.00
Australia	1.58	0.00	0.06	1.38	9.21	6.55	58.65
India	6.48	0.01	0.19	0.26	2.32	3.98	10.15
Switzerland	0.18	0.01	2.66	17.20	18.30	34.56	65.28
Germany	0.23	0.02	6.58	25.82	32.24	14.07	59.82

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.66	0.34	0.46	1.27	0.58	0.81	1.54
USD Index	96.02	0.07	0.08	0.55	0.07	2.40	6.29
YUAN	6.37	0.00	0.03	0.05	0.30	1.43	2.64
GBP	1.35	0.00	0.07	1.42	1.01	0.64	0.01
EUR	1.13	0.00	0.01	0.39	0.34	3.03	7.26
YEN	114.83	0.04	0.03	0.64	1.13	2.90	9.60

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2217.00	2.00	0.09	6.81	19.88	53.00	62.30
Baltic Dirty	786.00	2.00	0.25	2.12	6.50	27.60	68.67
SG Dubai HY	6.23	0.20	3.32	8.65	51.21	282.21	632.94

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	36302.38	351.82	0.98	2.65	4.02	5.84	19.40
Nasdaq	15871.26	217.89	1.39	4.62	2.45	9.11	23.04
S&P 500	4791.19	65.40	1.38	3.69	4.28	10.08	28.27
FTSE100	7372.10	1.24	0.02	1.41	4.66	4.37	13.38
CAC40	7173.95	32.79	0.46	2.99	6.43	10.25	28.36
DAX	15950.26	113.62	0.72	4.65	4.53	4.59	15.65
Mexico IPC	53259.56	406.18	0.77	3.17	7.61	4.58	21.37
Brazil Bovespa	105554.4	663.10	0.63	1.54	3.26	4.15	11.39
Russian RTS	1610.98	7.99	0.50	2.38	1.35	8.28	15.78
Japan Nikkei	29069.16	392.70	1.37	1.93	1.10	3.69	8.25
Hang Seng	23280.56	56.80	0.24	2.36	3.32	3.83	11.77
Taiwan Index	18196.81	147.87	0.82	2.29	4.76	5.91	25.64
Shanghai Comp	3630.11	14.14	0.39	0.14	1.85	0.77	6.85
KOSPI	3020.24	20.69	0.69	1.52	2.85	2.51	7.54
Malaysia KLCI	1539.89	5.98	0.39	3.17	1.83	0.45	6.33
Jakarta Comp	6598.34	22.90	0.35	0.67	0.56	7.94	8.28
Philippine SE	7286.50	31.70	0.44	1.67	0.11	5.83	2.31
Thai Exch	1641.52	5.02	0.31	1.19	1.92	1.55	13.00

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	76.51	0.95	1.26	12.15	12.28	1.63	60.69
BRENT Crude	79.45	0.84	1.07	7.38	10.97	3.46	58.50
Natural Gas	4.08	0.01	0.15	6.05	25.76	32.88	41.48

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1817.31	5.08	0.28	1.56	0.81	4.80	3.01
Silver(\$/Ounce)	23.14	0.08	0.33	2.77	0.06	3.06	11.82
Aluminium	2840.50	4.20	0.15	4.81	4.91	2.03	40.22
Copper	9595.00	43.00	0.45	1.35	3.03	2.69	23.48
Zinc	3555.75	12.75	0.36	3.70	4.84	13.89	26.18
Lead	2308.75	12.25	0.53	0.76	0.66	6.43	18.47

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	226.75	0.30	0.13	1.18	6.67	12.56	72.83
Cotton	112.33	0.05	0.04	6.43	0.49	13.81	51.18
Sugar	19.30	0.09	0.47	3.82	0.26	2.72	37.66
Wheat	798.75	5.25	0.65	2.70	4.94	11.09	28.11
Soybean	1380.25	8.75	0.64	6.60	9.28	6.79	29.18

Sterlite Power acquires Nangalbibra-Bongaigaon transmission project

Power transmission infrastructure developer Sterlite Power has acquired the Nangalbibra-Bongaigaon inter-state transmission project from PFC Consulting. Nangalbibra-Bongaigaon Transmission Ltd is a Special Purpose Vehicle (SPV). Through this SPV, the company will execute the inter-state transmission system (ISTS) project which it won through tariff-based competitive bidding (TBCB) in October 2021. The company, however, did not disclose the financial details of the transaction. The project involves setting up of around 300 ckt km (Circuit km) of transmission lines network and greenfield substation with 320 MVA transformation capacity across North-Eastern terrain of Assam and Meghalaya. The project will transmit over 1,000 MW of power from Assam to western parts of Meghalaya. The project includes 250 ckt km of 400kV D/c transmission line connecting Bongaigaon in Assam to a greenfield substation at Nangalbibra in Meghalaya, across the river Brahmaputra. It will also include a 220/132 kV substation at Nangalbibra in Meghalaya, and a 50 ckt km of 132kV D/c line connecting Hatsinghmari in Assam to Ampati in Meghalaya. Sterlite Power now has a portfolio of 27 projects across India and Brazil, which includes projects under various stages of development and those that have been sold.

Cipla to launch Molnupiravir under Cipmolnu brand name for COVID-19 treatment

Cipla plans to launch antiviral drug Molnupiravir for the treatment of adult patients with COVID-19, who have high risk of progression of the disease including hospitalisation or death, under the brand name Cipmolnu. The Mumbai-based firm said it plans to soon make Cipmolnu 200mg capsules available at all leading pharmacies and COVID treatment centers across the country. The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India. Earlier during the year, Cipla entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir in India and to over 100 low and middle-income countries (LMICs). The drug major has received emergency use authorisation (EUA) permission from the Drug Controller General of India (DCGI) to launch the antiviral drug in the country. The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies.

Biological E aims to produce 100 mn doses/month of Corbevax from Feb 2022

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022 which will enable the city-based company to deliver 300 Million doses as promised to the Centre. Corbevax, India's first indigenously developed protein sub-unit vaccine against the virus, received the approval from the Drugs Controller General of India (DCGI) today. According to a press release issued by the vaccine maker soon, the company plans to deliver more than one billion additional doses globally. The vaccine has been developed by Biological E. Limited in collaboration with Texas Children's Hospital Centre for Vaccine Development (Texas Children's CVD) and Baylor College of Medicine (Baylor) in Houston, Texas. Corbevax has completed two Phase III clinical trials involving more than 3000 subjects between the ages of 18 and 80 at 33 study sites across India. The vaccine was found to be safe, well tolerated and immunogenic.

Annapurna Finance raises Rs 260 cr in latest funding round

Annapurna Finance has raised Rs 260 crore (USD 35 million) from a clutch of investors to mainly fund its digital transformation and green financing. Annapurna Finance said the USD 35 million investment from Encourage Capital, Accion, and existing investor Oikocredit is the third fundraising during 2021. After attracting a USD 30 million investment from Nuveen Global Impact Fund in March and a USD 20 million from DEG in November, the total fundraise this year has reached USD 85 million. The MFI lender has a pan India rural distribution network, offering micro-credit loans, home improvement, and MSME loans to individuals and small businesses. As part of its larger vision, Annapurna is adding green finance products to its offering and also advancing its digital transformation journey.

ITC commissions first off-site solar plant in Tamil Nadu

ITC Limited has commissioned its first off-site solar plant in Tamil Nadu set up at an investment of Rs 76 crore, the company said on Tuesday. The 14.9 MW solar plant in Dindigul about 450 km from Chennai, would help reduce the carbon dioxide emissions over the course of the time and it has already helped ITC to achieve the feat of meeting 90 per cent of its electricity requirement. The project, in line with ITC Chairman Sanjiv Puri's 'Sustainability 2.0' Vision, under which ITC plans to meet 100 per cent of the entire grid electricity requirements from renewable sources by 2030 and contribute to combat the threat of climate change. ITC's renewable portfolio comprises of 138 MW of wind power plants and 14 MW of solar plants with 53 MW of additional solar capacity under execution. Currently, projects were underway in other sources of renewable energy like biomass boilers. The company has made investments of over Rs 1,000 crore in renewable energy assets to date.

Sun Pharma gets DCGI nod to market molnupiravir for COVID-19 treatment

Sun Pharma has received emergency use authorisation (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of MSD and Ridgeback's antiviral drug molnupiravir under the brand name Molxvir in India. Earlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply a generic version of molnupiravir in over 100 low and middle-income countries (LMICs) including India. The DCGI has approved molnupiravir for treatment of adult patients with COVID-19 and who have high risk of progression of the disease including hospitalisation or death. Molnupiravir is an important addition to the portfolio of oral therapies available for treating Covid-19 patients

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Gaekwar Mills Ltd	Corporate meeting effective of 29-12-2021
Bambino Agro Industries Ltd	Corporate meeting effective of 29-12-2021
MMTC Ltd	Corporate meeting effective of 29-12-2021
Radhe Developers India Ltd	Corporate meeting effective of 29-12-2021
Janus Corp Ltd	Corporate meeting effective of 29-12-2021
Ambica Agarbathies Aroma & Industries Ltd	Corporate meeting effective of 29-12-2021
Muthoot Capital Services Ltd	Corporate meeting effective of 29-12-2021
XPRO India Ltd	Corporate meeting effective of 29-12-2021
Bervin Investment & Leasing Ltd	Corporate meeting effective of 29-12-2021
Mysore Paper Mills Ltd/The	Corporate meeting effective of 29-12-2021
Aadi Industries Ltd	Corporate meeting effective of 29-12-2021
Setco Automotive Ltd	Corporate meeting effective of 29-12-2021
TCI Finance Ltd	Corporate meeting effective of 29-12-2021
Richfield Financial Services Ltd	Corporate meeting effective of 29-12-2021

Domestic Events

- No Events

Global Events

- The U.S. MBA Mortgage Applications for December 24, 2021.
- The U.S. Goods Trade Balance for November 2021.
- The U.S. Pending Home Sales for November 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Jaydeb Dey and Deepankar Saha Research Analyst(S) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
